Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market. It hasn’t exactly worked out that way.

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

Online prescriptions – for everything from weight loss to medicinal cannabis – is now a big business backed by Woolworths and ...

Novo Nordisk reduced its starter dose prices through telehealth platforms to encourage patients to wean themselves off compounded copycats.

Dow Jones Top Company Headlines at 11 PM ET: GM Is Pushing Hard to Tank California’s EV Mandate | Trump ... The Senate will vote as early as next week on a measure to revoke the state's emissions ...

As Ozempic and other GLP-1 drugs explode ... forces of social media-driven demand and regulatory loopholes in the pharmaceutical market? The ongoing battle against counterfeit GLP-1 drugs and ...